0001703057false00017030572024-06-132024-06-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 13, 2024
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
2215 Yukon Street
Vancouver, BC
V5Y 0A1
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 5.07    Submission of Matters to a Vote of Security Holders.

AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 13, 2024. As of April 15, 2024, the record date for the Annual Meeting, there were 293,921,356 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company’s shareholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2024: (i) to elect Véronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors of the Company to serve for a three-year term expiring at the Company’s annual meeting of shareholders in 2027 and until his or her successor has been elected and qualified (“Proposal 1”), (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 2”), and (iii) to approve on a non-binding advisory basis, the compensation of the Company’s named executive offices, or Say-on-Pay (“Proposal 3”).

Proposal 1
The Company’s shareholders approved the election of Véronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class I directors as follows:

NomineeForAgainstAbstain
Véronique Lecault, Ph.D.
167,328,5066,868,58215,059,808
Andrew Lo, Ph.D.
152,914,3116,017,04730,325,538

The broker non-votes for this Proposal 1 totaled 23,405,619 common shares.


Proposal 2
The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:

ForAgainstAbstain
211,978,251306,801377,463


Proposal 3
The Company’s shareholders approved` Proposal 3. The votes cast at the Annual Meeting were as follows:

ForAgainstAbstain
176,566,7247,454,8525,235,320


The broker non-votes for this Proposal 3 totaled 23,405,619 common shares.

No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 13, 2024ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name AbCellera Biologics Inc.
Document Period End Date Jun. 13, 2024
Entity Incorporation, State or Country Code A1
Entity File Number 001-39781
Entity Address, Postal Zip Code V5Y 0A1
Entity Central Index Key 0001703057
Amendment Flag false
Entity Address, Address Line One 2215 Yukon StreetVancouver, BC
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
City Area Code (604)
Local Phone Number 559-9005
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol ABCL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di AbCellera Biologics
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di AbCellera Biologics